Badizadegan Kamran, Goodson James L, Rota Paul A, Thompson Kimberly M
Kid Risk, Inc., Orlando, FL, USA.
Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Expert Rev Vaccines. 2020 Feb;19(2):175-194. doi: 10.1080/14760584.2020.1732215. Epub 2020 Mar 17.
: In the last two decades, the evidence related to using vaccine patches with multiple short projections (≤1 mm) to deliver vaccines through the skin increased significantly and demonstrated their potential as an innovative delivery platform.: We review the vaccine patch literature published in English as of 1 March 2019, as well as available information from key stakeholders related to vaccine patches as a platform. We identify key research topics related to basic and translational science on skin physical properties and immunobiology, patch development, and vaccine manufacturing.: Currently, vaccine patch developers continue to address some basic science and other platform issues in the context of developing a potential vaccine patch presentation for an existing or new vaccine. Additional clinical data and manufacturing experience could shift the balance toward incentivizing existing vaccine manufactures to further explore the use of vaccine patches to deliver their products. Incentives for innovation of vaccine patches differ for developed and developing countries, which will necessitate different strategies (e.g. public-private partnerships, push, or pull mechanisms) to support the basic and applied research needed to ensure a strong evidence base and to overcome translational barriers for vaccine patches as a delivery platform.
在过去二十年中,使用带有多个短突起(≤1毫米)的疫苗贴片经皮递送疫苗的相关证据显著增加,并证明了其作为创新递送平台的潜力。我们回顾了截至2019年3月1日以英文发表的疫苗贴片文献,以及来自关键利益相关者的与疫苗贴片作为一个平台相关的可用信息。我们确定了与皮肤物理特性和免疫生物学、贴片开发以及疫苗生产的基础和转化科学相关的关键研究主题。目前,疫苗贴片开发者在为现有或新疫苗开发潜在的疫苗贴片形式的背景下,继续解决一些基础科学和其他平台问题。更多的临床数据和生产经验可能会使天平向激励现有疫苗制造商进一步探索使用疫苗贴片来递送其产品的方向倾斜。疫苗贴片创新的激励措施在发达国家和发展中国家有所不同,这将需要不同的策略(例如公私伙伴关系、推动或拉动机制)来支持所需的基础和应用研究,以确保有强大的证据基础,并克服疫苗贴片作为递送平台的转化障碍。